Ganaplacide/lumefantrine combination a potential new malaria treatment
In a study conducted in children under 12 years old, the ganaplacide/lumefantrine combination significantly reduced malaria infection.
List view / Grid view
In a study conducted in children under 12 years old, the ganaplacide/lumefantrine combination significantly reduced malaria infection.
An international research team has conducted successful phase II clinical tests of a new anti-malaria medication...
15 June 2016 | By Victoria White, Digital Content Producer
Novartis' KAF156 is one of the first antimalarial drug candidates to enter Phase IIb clinical development in more than 20 years...
8 July 2015 | By Victoria White
Sanofi is to extend its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new single, fixed-dose combination therapy for malaria...
28 April 2014 | By GlaxoSmithKline
GlaxoSmithKline and Medicines for Malaria Venture announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine...
5 May 2011 | By Sanofi-Aventis
Sanofi-aventis and MMV announced that they have signed an alliance agreement...